Prospective evaluation of a D-optimal designed population pharmacokinetic study

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 30, Issue 2, 2003, Pages 145-161

  Green, Bruce ^a   Duffull, Stephen B ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

D optimal design; Enoxaparin; Pharmacokinetics; Population analysis

Indexed keywords

CREATININE; ENOXAPARIN;

ACCURACY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL TRIAL; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG CLEARANCE; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PHARMACOKINETICS; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL;

ADULT; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PROSPECTIVE STUDIES; RESEARCH DESIGN; TIME FACTORS;

EID: 0038336553     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024467714170     Document Type: Article

References (18)

1. B. Green and S. Duffull. Development of a dosing strategy for enoxaparin in obese patients. Br. J. Clin. Pharacol. In Press (2003).
2. D. D'Argenio. Optimal sampling times for pharmacokinetic experiments. J. Pharmacokin. Biopharm. 9:739-756 (1981).
3. F. Mentré, A. Mallet, and D. Baccar. Optimal design in random-effects regression models. Biometrika. 84:429-442 (1997).
4. S. Retout, S. Duffull, and F. Mentré. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Comput. Methods Programs Biomed. 65:141-151 (2001).
5. D. Z. D'Argenio. Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. Math. Biosci. 99:105-118 (1990).
6. M. Tod, F. Mentré, Y. Merle, and A. Mallet. Robust optimal design for the estimation of hyperparameters in population pharmacokinetics. J. Pharmacokin. Biopharm. 26:689-716 (1998).
7. A. C. Atkinson and A. N. Donev. Optimum Experimental Designs. Oxford: Clarendon Press. (1992).
8. Y. Merlé and M. Tod. Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design. J. Pharmacokinet. Pharmacodyn. 28:363-388 (2001).
9. F. Mentré, C. Dubruc, and J. Thenot. Population Pharmacokinetic Analysis and Optimisation of the Experimental Design for Mizolastine Solution in Children. J. Pharmacokinet. Pharmacodyn. 28:299-319 (2001).
10. G. L. Drusano, A. Forrest, K. I. Plaisance, and J. Wade. A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients. Clin. Pharmacol. Ther. 45:635-641 (1989).
11. G. J. Yuen, G. L. Drusano, A. L. Forrest, K. I. Plaisance, and E. S. Caplan. Prospective use of optimal sampling theory: Steady-state ciprofloxaxin pharmacokinetics in critically ill trauma patients. Clin. Pharmacol. Ther. 46:451-457 (1989).
12. A. N. Teien and M. Lie. Evaluation of an amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin III. Thromb. Haemost. 10:399 (1977).
13. M. Laposata, D. Green, E. M. Van Cott, T. W. Barrowcliffe, S. H. Goodnight, and R. C. Sosolik. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy. The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch. Pathol. Lab. Med. 122:799-807 (1998).
14. S. B. Duffull, S. Retout, and F. Mentré. The use of simulated annealing for finding optimal population designs. Comput. Methods Programs Biomed. 69:25-35 (2002).
15. S. L. Beal and L. B. Sheiner. NONMEM User's Guide, Part V: Population Conditional Estimation Methods. Division of Clinical Pharmacology, University of California at San Francisco. 1992.
16. I. Yano, S. L. Beal, and L. B. Sheiner. Evaluating pharmacokinetic/pharmacodynamic models using the postertior predictive check. J. Pharmacokinet. Pharmacodyn. 28:171-192 (2001).
17. P. Girard, T. F. Blaschke, H. Kastrissios, and L. B. Sheiner. A Markov mixed effect regression model for drug compliance. Stat. Med. 17:2313-2333 (1998).
18. C. Peck, S. L. Beal, L. B. Sheiner, and A. I. Nichols. Extended Least Squares Nonlinear Regression: A Possible Solution to the "Choice of Weights" Problem in Analysis of Individual Pharmacokinetic Data. J. Pharmacokin. Biopharm. 12:545-558 (1984).